Study on Noom Program's Impact on GLP-1 Medication Users
The study evaluates the effectiveness of the Noom digital lifestyle program for adults on GLP-1 medications.
Company
Pharmaceutical intelligence for Noom with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.